Best Diffuse Large B Cell Lymphoma Podcasts (2025)

1
Current Perspectives on the Future of Cancer Research 1:05:29

15d ago1:05:29

1:05:29

- Understanding the Future of Cancer Research & Clinical Trials- Increased Focus on Earlier Detection & Treatment of Cancer- Health Care Disparities Research- Enhanced Knowledge of the Molecular Portrait of Cancer- Artificial Intelligence (AI) Driven Approaches for Diagnosis & Treatment of Cancer- Microsatellite Instability (MSI): Mutations in DNA …

1
Clonal hematopoiesis in frequent blood donors, immune microenvironment and bispecific antibody response in diffuse large B-cell lymphoma, and blinatumomab as part of early consolidation therapy in CD19 ... 20:57

29d ago20:57

20:57

In this week's episode we’ll learn about how frequent blood donation affects clonal hematopoiesis in older, male blood donors; the effect of immune microenvironment on response to bispecific antibodies in diffuse large B-cell lymphoma; and the feasibility of adding blinatumomab to early consolidation therapy in CD19-positive Ph-negative B-cell acut…

1
MEK Inhibitors in Neurofibromatosis Type 1: Latest Advances and Real-World Applications in NF1-PN Management 1:03:44

1d ago1:03:44

1:03:44

In this CEC Oncology recorded, case-based symposium, expert faculty will discuss diagnosis and disease challenges over a person’s lifespan; explore the integration of MEK inhibitors in the management of NF1-associated PNs in pediatric patients; and consider comprehensive interprofessional care plans that include disease monitoring, toxicity managem…

1
Aggressive non-Hodgkin lymphoma: defining and managing high-risk subsets 41:28

1d ago41:28

41:28

Blood editor Dr. Laurie Sehn discusses the topic of "Aggressive non-Hodgkin lymphoma: defining and managing high-risk subsets" featuring Drs. Mark Roschewski, Grzegorz Nowakowski, and Neha Mehta-Shah, who each contributed to the articles featured in the review series on high-risk aggressive lymphoma. See the full review series on high risk lymphoma…

1
A key role for T-cell TET3 in chronic GVHD; a BTK inhibitor for ITP; co-inhibition of pre-TCR and IL-7R pathways in a T-ALL patient subset 20:30

9d ago20:30

20:30

In this week's episode, we' ll learn about how TET3 has a key role in GVHD. In mice, a deficiency of Tet3 in donor T cells inhibited pathogenic immunoglobulin class switching and suppressed lung fibrosis. Accordingly, TET3 may be a new therapeutic target in chronic GVHD. After that: rilzabrutinib, a BTK inhibitor for ITP. In a randomized, placebo-c…

1
Special Episode: Eliminating the Need for Sequential Confirmation of Response in Multiple Myeloma 9:47

10d ago9:47

9:47

In this special episode, Dr. Shaji Kumar from the Mayo Clinic speaks with Blood editor Dr. Laurie Sehn on a paper recently published in Blood, "Eliminating the Need for Sequential Confirmation of Response in Multiple Myeloma". The findings demonstrate eliminating the need for sequential confirmation of response in multiple myeloma. The study, invol…

1
HER2-Positive Metastatic Breast Cancer: What’s New in Treatment and Quality-of-Life 57:16

14d ago57:16

57:16

- HER2-Positive Metastatic Breast Cancer- Biomarker, Genomic & Diagnostic Testing: Grade & Hormone Receptors- Standard Treatment Options, Including Targeted Therapy- How Biomarker Testing Informs Treatment Decisions- New & Emerging Targeted Treatments- Updates on Investigational New Drugs in Clinical Trials- How Research Contributes to Your Treatme…

1
Current Perspectives on the Future of Cancer Research 1:05:29

15d ago1:05:29

1:05:29

- Understanding the Future of Cancer Research & Clinical Trials- Increased Focus on Earlier Detection & Treatment of Cancer- Health Care Disparities Research- Enhanced Knowledge of the Molecular Portrait of Cancer- Artificial Intelligence (AI) Driven Approaches for Diagnosis & Treatment of Cancer- Microsatellite Instability (MSI): Mutations in DNA …

1
Current Perspectives on the Future of Cancer Research 1:05:29

15d ago1:05:29

1:05:29

- Understanding the Future of Cancer Research & Clinical Trials- Increased Focus on Earlier Detection & Treatment of Cancer- Health Care Disparities Research- Enhanced Knowledge of the Molecular Portrait of Cancer- Artificial Intelligence (AI) Driven Approaches for Diagnosis & Treatment of Cancer- Microsatellite Instability (MSI): Mutations in DNA …

1
How I Treat Series on Geriatric Hematology 17:19

15d ago17:19

17:19

In this How I Treat Series episode Dr. Thomas Ortel leads a discussion with author Dr. Patrick Foy on his paper “How I diagnose and treat thrombocytopenia in geriatric patients”. See the full How I Treat series on geriatric hematology in volume 143 issue 3 of Blood Journal.By American Society of Hematology

1
Single cell multi-omic analysis of leukemia stem cells, cyclophosphamide for non-immune effector cell-associated neurotoxicity, and glycosylation as a mediator of von Willebrand factor clearance 16:06

15d ago16:06

16:06

In this week's episode, we’ll learn more about the identification and characterization of stem cell-like leukemia blasts using single cell multi-omics, cyclophosphamide as a treatment for non-immune effector cell-associated neurotoxicity in patients treated with B-cell maturation antigen, or BCMA, targeted CAR T-cell therapies, and how differences …

1
Emerging Treatments for Metastatic Melanoma 59:45

17d ago59:45

59:45

- Overview of Metastatic Melanoma, Including Diagnosing & Staging- New Treatment Approaches- Targeted Therapy & the Role of Precision Medicine- The Role of Immunotherapy- Clinical Trial Updates- Follow-Up Care- Tips for Caring for Your Skin During Cancer Treatments, Including Sun & Wind Safety Recommendations- Controlling Side Effects, Symptoms, Di…

1
Understanding How Health Care Disparities May Influence Your Cancer Treatment and Care 51:55

18d ago51:55

51:55

- Disproportionate Burden of Cancer & Infectious Diseases on People of Color- Social Determinants of Health, Including Languages Spoken, Health Literacy, Culture, Race, Gender Orientation, LGBTQI+, Religion, Access to Medical Care- Influence of the Local & Regional Environment in Which You Live- How Race May Impact Your Access to Oncology Care, Tre…

1
Understanding How Health Care Disparities May Influence Your Cancer Treatment and Care 51:55

18d ago51:55

51:55

- Disproportionate Burden of Cancer & Infectious Diseases on People of Color- Social Determinants of Health, Including Languages Spoken, Health Literacy, Culture, Race, Gender Orientation, LGBTQI+, Religion, Access to Medical Care- Influence of the Local & Regional Environment in Which You Live- How Race May Impact Your Access to Oncology Care, Tre…

1
Understanding How Health Care Disparities May Influence Your Cancer Treatment and Care 51:55

18d ago51:55

51:55

- Disproportionate Burden of Cancer & Infectious Diseases on People of Color- Social Determinants of Health, Including Languages Spoken, Health Literacy, Culture, Race, Gender Orientation, LGBTQI+, Religion, Access to Medical Care- Influence of the Local & Regional Environment in Which You Live- How Race May Impact Your Access to Oncology Care, Tre…

1
New Perspectives in the Treatment of Advanced Skin Cancer: Advanced Basal Cell and Squamous Cell Cancer 56:00

21d ago56:00

56:00

- Overview of Advanced Skin Cancers, Including Basal Cell & Squamous Cell Cancers- New Treatment Approaches- Emerging Role of Targeted Therapy- Clinical Trial Updates- Managing Treatment Side Effects, Discomfort & Pain- Tips for Caring for Your Skin During Cancer Treatments- Sun & Wind Safety Tips- Communicating with Your Health Care Team About Qua…

1
Role of the Multidisciplinary Team in Achieving Comprehensive and Individualized Care of Patients with HR-positive/HER2-negative Metastatic Breast Cancer and Preexisting Comorbidities 35:15

22d ago35:15

35:15

In this podcast episode, Sara A. Hurvitz, MD, FACP, La-Urshalar B. Brock, FNP-BC, CNM, and Jordan Hill, PharmD, BCOP, discuss the important role of the multidisciplinary team in achieving comprehensive and individualized care of patients with HR-positive/HER2-negative metastatic breast cancer and preexisting comorbidities, including: Key Comorbidit…

1
New insights on PU.1-mutated agammaglobulinemia; venetoclax-based induction therapy in younger AML patients; the link between ABO Blood groups and risk of future VTE 19:46

22d ago19:46

19:46

In this week's episode, we'll hear about new insights into PU.1-mutated agammaglobulinemia. Researchers show that haploinsufficiency of the master transcriptional regulator PU.1 causes agammaglobulinemia and dendritic cell deficiencies. These patients experience an array of infectious and non-infectious complications, but not leukemia. After that: …

1
Dual BCR::ABL1 Inhibition Shows Promise in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia 18:31

27d ago18:31

18:31

In this episode, Contributing Editor Scott Furlan, MD, PhD, an assistant professor at the Fred Hutch Cancer Center and Department of Pediatrics at the University of Washington in Seattle, talks with Daniel J. DeAngelo, MD, PhD, chief of the leukemia division at the Dana-Farber Cancer Institute and a professor of medicine at Harvard Medical School i…

1
How I Treat Transfusion Medicine (part 2) 33:57

29d ago33:57

33:57

In part two of the How I Treat Series on Transfusion Medicine Dr. Erica Wood interviews the "How I Manage Major Hemorrhage" author group: Drs. Jeannie Callium, Keyvan Karkouti, and Ron George. Find the full published review series in Volume 145 Issue 20 of Blood Journal.By American Society of Hematology

1
What’s New in Precision Medicine 1:01:06

1M ago1:01:06

1:01:06

- Understanding Precision Medicine: Overview & Value of Precision Medicine- How Precision Medicine is Different from Targeted Treatments?- Precision Medicine’s Role in Informing Treatment Decisions: Predicting Response to Treatment- The Role of Precision Medicine in Deciding the Treatment for Lung Cancer, Leukemia & Colon Cancer- Talking with Your …

1
Uncovering Safety and Signposts to the Future: AEs With HER2-Targeted ADCs and Future Applications 21:54

1M ago21:54

21:54

In this episode, Catherine Fahey, MD, PhD; Alexandra Leary, MD, PhD; Funda Meric-Bernstam, MD; and Zev A. Wainberg, MD, discuss the evolving safety considerations and future directions of HER2-targeted antibody–drug conjugates (ADCs) across genitourinary, gastrointestinal, and gynecologic cancers. Toxicity Profiles of HER2-Targeted ADCs: Common and…

1
When to STOP Treatment for Immune Thrombocytopenia in Patients Experiencing a Complete Response on Thrombopoietin Receptor Agonists 10:34

1M ago10:34

10:34

In this episode, Contributing Editor Michael Scott, MD, a hematologist at St. Michael’s Hospital in Toronto, Canada, and an assistant professor at the University of Toronto, talks with Marc Michel, MD, MSc, head of the internal medicine and clinical immunology department at Henri Mondor University Hospital in Créteil, France. They talk about long-t…

1
How I Treat Transfusion Medicine (part 1) 32:12

1M ago32:12

32:12

In this two-part series, Dr. Erica Wood talks with Drs. Masja de Haas, Helen Savoia, and Stella Chou about their articles in the How I Treat Series on Transfusion Medicine. Topics include noninvasive prenatal testing for red blood cell and platelet antigens, transfusion cases in sickle cell disease, and pregnant patients who are alloimmunized to RB…

1
Discontinuing lenalidomide maintenance in MM; congenital neutropenia syndrome linked to COPZ1 mutations; low GVHD rates with ruxolitinib after allogeneic HCT 18:15

1M ago18:15

18:15

In this week's episode, we'll learn about stopping myeloma maintenance therapy in the modern era. New research suggests that many patients in remission can discontinue lenalidomide, remaining treatment-free, without jeopardizing disease response. After that: a novel congenital neutropenia syndrome. Mutations in the COPZ1 gene impact myeloid differe…

1
Update on Follicular Lymphoma 51:28

1M ago51:28

51:28

- Overview of Follicular Lymphoma- Treatment Options for Newly Diagnosed- Treatment Options for Relapsed/Refractory Disease- Clinical Trial Updates: How Research Increases Treatment Options- New & Emerging Treatments- Factors that May Affect Treatment Planning- Side Effect Prevention & Management- Tips to Improve Communicating with the Health Care …

1
Update on Follicular Lymphoma 51:28

1M ago51:28

51:28

- Overview of Follicular Lymphoma- Treatment Options for Newly Diagnosed- Treatment Options for Relapsed/Refractory Disease- Clinical Trial Updates: How Research Increases Treatment Options- New & Emerging Treatments- Factors that May Affect Treatment Planning- Side Effect Prevention & Management- Tips to Improve Communicating with the Health Care …

1
Advances in the Treatment of Gastric Cancer 57:50

1M ago57:50

57:50

- Overview of Gastric Cancer, Including Diagnosis & Staging- Current Standard of Care, Including Chemotherapy- New Treatment Approaches & the Role of Targeted Treatment & Immunotherapy- Precision Medicine: Predicting Response to Treatment- The Role of Clinical Trials: How Research Contributes to Treatment Options- Controlling Treatment Side Effects…

1
Diffuse Large B-Cell Lymphoma (DLBCL): Treatment Updates 1:00:44

1M ago1:00:44

1:00:44

- Overview of Diffuse Large B-Cell Lymphoma- Staging & Grading- Current Standard of Care- Treatment Options for Resistant Disease- New & Emerging Treatment Approaches- The Role of Clinical Trials- How Research Contributes to Treatment Choices- Tips to Manage Treatment Side Effects, Symptoms, Discomfort & Pain- The Increasing Role of Telehealth/Tele…

1
Diffuse Large B-Cell Lymphoma (DLBCL): Treatment Updates 1:00:44

1M ago1:00:44

1:00:44

- Overview of Diffuse Large B-Cell Lymphoma- Staging & Grading- Current Standard of Care- Treatment Options for Resistant Disease- New & Emerging Treatment Approaches- The Role of Clinical Trials- How Research Contributes to Treatment Choices- Tips to Manage Treatment Side Effects, Symptoms, Discomfort & Pain- The Increasing Role of Telehealth/Tele…

1
Diffuse Large B-Cell Lymphoma (DLBCL): Treatment Updates 1:00:44

1M ago1:00:44

1:00:44

- Overview of Diffuse Large B-Cell Lymphoma- Staging & Grading- Current Standard of Care- Treatment Options for Resistant Disease- New & Emerging Treatment Approaches- The Role of Clinical Trials- How Research Contributes to Treatment Choices- Tips to Manage Treatment Side Effects, Symptoms, Discomfort & Pain- The Increasing Role of Telehealth/Tele…

1
Measurable residual disease and maintenance therapy in acute myeloid leukemia (AML), stemness and chemotherapy resistance in AML, and effects of babesiosis on red blood cells in sickle cell disease 19:58

1M ago19:58

19:58

In this week's episode, we’ll learn more about how measurable residual disease might help guide decisions about post-transplant gilteritinib maintenance in FLT3-ITD acute myeloid leukemia, or AML; how stemness contributes to chemotherapy resistance in AML; and effects of babesiosis on red blood cells from individuals with sickle cell disease, sickl…

1
Taking a New Path: Evaluating Clinical Data With HER2-Targeted ADCs in Genitourinary, Gastrointestinal, and Gynecological Malignancies 29:36

2M ago29:36

29:36

In this episode, Catherine Fahey, MD, PhD; Alexandra Leary, MD, PhD; Funda Meric-Bernstam, MD; and Zev A. Wainberg, MD, explore the mechanisms of HER2-targeted antibody–drug conjugates (ADCs) and emerging clinical data with these agents across genitourinary, gastrointestinal, and gynecologic cancers. Mechanisms of action of ADCs: how ADCs selective…

1
Metastatic Breast Cancer: Treatment Updates 1:05:14

2M ago1:05:14

1:05:14

- Overview of Metastatic Breast Cancer- Current Standard of Care- New Treatment Approaches- Updates on Clinical Trials- How Clinical Research Increases Your Treatment Options- Biomarkers, Diagnostic Testing & Technologies: Why They Are Important in Informing Treatment Decisions for Metastatic Breast Cancer- Preventing & Managing Treatment Side Effe…

1
Uniquely programmed blood stem cells in the human lung; inclusive molecular classifier for DLBCL; new insights on NETs in the liver vasculature 18:12

2M ago18:12

18:12

In this week's episode, we'll hear about how researchers look toward the lung, and find uniquely programmed blood stem cells. This study is the first to fully characterize hematopoietic stem and progenitor cells in the adult human lung. After that: researchers develop a neural network-based probabilistic classifier, DLBclass, that assigns all diffu…

1
Cancer & the Workplace: Understanding Your Legal Protections 56:39

2M ago56:39

56:39

- The Meaning of Work- Talking with Your Health Care Team About Work- Managing Your Cancer Treatments While Working- Understanding Your Legal Protections in the Workplace, Including Americans with Disabilities Act (ADA)- Family Medical Leave Act (FMLA) & Intermittent FMLA- Equal Employment Opportunity Commission (EEOC) State & Local Laws- Disclosur…

1
Cancer & the Workplace: Understanding Your Legal Protections 56:39

2M ago56:39

56:39

- The Meaning of Work- Talking with Your Health Care Team About Work- Managing Your Cancer Treatments While Working- Understanding Your Legal Protections in the Workplace, Including Americans with Disabilities Act (ADA)- Family Medical Leave Act (FMLA) & Intermittent FMLA- Equal Employment Opportunity Commission (EEOC) State & Local Laws- Disclosur…

1
Cancer & the Workplace: Understanding Your Legal Protections 56:39

2M ago56:39

56:39

- The Meaning of Work- Talking with Your Health Care Team About Work- Managing Your Cancer Treatments While Working- Understanding Your Legal Protections in the Workplace, Including Americans with Disabilities Act (ADA)- Family Medical Leave Act (FMLA) & Intermittent FMLA- Equal Employment Opportunity Commission (EEOC) State & Local Laws- Disclosur…

1
Understanding HER2 Low Breast Cancer 55:26

2M ago55:26

55:26

- Overview of HER2 Low Breast Cancer- What is the HER2 Status of My Cancer? What does this Mean?- Diagnostic Testing: What is an Immunohistochemistry (IHC) Test or Fluorescence In Situ Hybridization (FISH) Test- The Role of the Pathologist- The Role of the Genetic Counselor- Standard Treatment Options, Including Targeted Therapy- How Biomarker Test…

1
No Scientific Link Found Between Sickle Cell Trait and Sudden Death 21:07

2M ago21:07

21:07

In this episode, Contributing Editor Samuel Wilson, MD, MSCR, an assistant professor of hematology at the University of North Carolina at Chapel Hill, talks with Michael DeBaun, MD, MPH, a professor of pediatrics and medicine at Vanderbilt University Medical Center and founder and director of the Vanderbilt-Meharry Sickle Cell Disease Center of Exc…

1
Diverse Populations Living with Multiple Myeloma 57:20

2M ago57:20

57:20

- Overview of Diverse Populations Living with Multiple Myeloma- How Race May Impact Your Access to the Treatment of Multiple Myeloma- Social Determinants of Health, Including Languages Spoken & Health Literacy- Current Standard of Care- New & Emerging Treatments- The Role of Transplantation- Preventing & Managing Treatment Side Effects, Symptoms, D…

1
Phosphoseryl-tRNA kinase inhibition in acute myeloid leukemia (AML), APOE gene variants and post-hematopoietic stem cell transplant outcomes in AML, and the role of chronic inflammation in sickle cell ... 19:06

2M ago19:06

19:06

In this week's episode we’ll learn more about how phosphoseryl-tRNA kinase inhibition promotes cell death in acute myeloid leukemia, or AML; APOE gene variants and their association with post-hematopoietic stem cell transplant outcomes in AML; and pathways by which chronic inflammation and oxidative stress may lead to cardiomyopathy in patients wit…

1
The Latest Evidence on Targeting B7-H3 in Small Cell Lung Cancer 18:34

2M ago18:34

18:34

In this episode, hear Lauren Byers, MD and Christine Hann, MD share their insights on the latest data regarding new therapies targeting B7-H3 in small cell lung cancer including: Rationale for targeting B7-H3 Overview of the structure of antibody-drug conjugates (ADCs) Results from the phase I/II IDeate-PanTumor01 trial of ifinatamab deruxtecan (I-…

1
Understanding the Cost of Care & Your Health Care Coverage 1:00:33

2M ago1:00:33

1:00:33

- Overview of the Medical & Indirect Costs of Treatment- What to Do When Cancer Treatment Seems Unaffordable – Self Advocacy- Talking with Your Health Care Team about Your Financial Concerns- The Benefits & Limitations of Your Health Plans, Insurance, Medicare & Medicaid Coverage- Tips on Appealing Your Insurance & Medicare Claims & Provider Denial…

1
Understanding the Cost of Care & Your Health Care Coverage 1:00:33

2M ago1:00:33

1:00:33

- Overview of the Medical & Indirect Costs of Treatment- What to Do When Cancer Treatment Seems Unaffordable – Self Advocacy- Talking with Your Health Care Team about Your Financial Concerns- The Benefits & Limitations of Your Health Plans, Insurance, Medicare & Medicaid Coverage- Tips on Appealing Your Insurance & Medicare Claims & Provider Denial…

1
Understanding the Cost of Care & Your Health Care Coverage 1:00:33

2M ago1:00:33

1:00:33

- Overview of the Medical & Indirect Costs of Treatment- What to Do When Cancer Treatment Seems Unaffordable – Self Advocacy- Talking with Your Health Care Team about Your Financial Concerns- The Benefits & Limitations of Your Health Plans, Insurance, Medicare & Medicaid Coverage- Tips on Appealing Your Insurance & Medicare Claims & Provider Denial…

1
The Lay of the Land: Overview of Biology of HER2 in Genitourinary, Gastrointestinal, and Gynecologic Malignancies 14:09

2M ago14:09

14:09

In this episode, Zev A. Wainberg, MD; Funda Meric-Bernstam, MD; Alexandra Leary, MD, PhD; and Catherine Fahey, MD, PhD, explore testing for HER2 alterations and the incidence of HER2-positive disease in the treatment of genitourinary, gastrointestinal, and gynecologic malignancies. HER2 Testing in Advanced Cancers: Recommendations for when and how …

1
Managing Eye and Vision Changes Related to Cancer Treatments 57:10

2M ago57:10

57:10

- Overview of Common Eye & Vision Changes Related to Cancer Treatments- Discussion of Common Eye & Vision Changes, Including Causes & Risk Factors- Tips to Manage Dry Eyes, Watery Eyes, Itching Eyes, Blepharitis, Loss of Eyelashes, Changes in Vision, Cataracts, Floaters & Flashing Lights- The Role of the Multidisciplinary Team- Tips to Manage Low V…

1
Managing Eye and Vision Changes Related to Cancer Treatments 57:10

2M ago57:10

57:10

- Overview of Common Eye & Vision Changes Related to Cancer Treatments- Discussion of Common Eye & Vision Changes, Including Causes & Risk Factors- Tips to Manage Dry Eyes, Watery Eyes, Itching Eyes, Blepharitis, Loss of Eyelashes, Changes in Vision, Cataracts, Floaters & Flashing Lights- The Role of the Multidisciplinary Team- Tips to Manage Low V…

1
Managing Eye and Vision Changes Related to Cancer Treatments 57:10

2M ago57:10

57:10

- Overview of Common Eye & Vision Changes Related to Cancer Treatments- Discussion of Common Eye & Vision Changes, Including Causes & Risk Factors- Tips to Manage Dry Eyes, Watery Eyes, Itching Eyes, Blepharitis, Loss of Eyelashes, Changes in Vision, Cataracts, Floaters & Flashing Lights- The Role of the Multidisciplinary Team- Tips to Manage Low V…

Podcasts Worth a Listen

Diffuse Large B Cell Lymphoma Podcasts

Podcasts Worth a Listen

Quick Reference Guide